X ray (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial bone marrow (BM) radiation
At least 14 days after local palliative radiation therapy (XRT) (small port); at least 150 days must have elapsed if prior traumatic brain injury (TBI), craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow radiation, including therapeutic doses of Iobenguane (MIBG)
>= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of M-Iodobenzylguanidine (MIBG); >= 3 months must have elapsed if prior craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if total-body irradiation (TBI) was received; >= 6 weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Subjects should not have any clinically relevant ongoing complications from prior radiation therapy (i.e., radiation esophagitis or other inflammation of the viscera)
>= 2 weeks must have elapsed for local palliative radiation therapy (XRT) (small port) and enrollment on study; at least 24 weeks must have elapsed since prior total body irradiation (TBI), radiation to >= 50% of pelvis, or craniospinal radiation; >= 6 weeks must have elapsed if the patient has received other substantial bone marrow radiation
Prior to registration, patients must be ? 14 days for local palliative radiation therapy (XRT) (small port); ? 90 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if ? 50% radiation of pelvis; ? 45 days must have elapsed if other substantial bone marrow radiation
Radiation therapy (XRT): at least 14 days after local palliative XRT (small port); 6 weeks must have elapsed since treatment with therapeutic doses of 131-meta-iodobenzylguanidine sulfate (I^131-MIBG); at least 150 days must have elapsed if prior traumatic brain injury (TBI), craniospinal XRT, or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial brain metastases (BM) radiation
Patients enrolled in the study will meet standard criteria for whole breast XRT or chest wall XRT for patients who have had mastectomies
>= 6 months must have elapsed if the patient has received involved field XRT or gamma knife that includes all target lesions (i.e., there is no restriction if a new lesion arises outside the radiation field or a non-irradiated lesion progresses); >= 6 months must have elapsed if the patient has received craniospinal XRT; >= 6 weeks must have elapsed if patient has received radiation to areas outside optic glioma
Radiotherapy: >=2 weeks must have elapsed since local palliative radiotherapy (XRT) (small port); >=3 months must have elapsed if prior Traumatic Brain Injury (TBI), craniospinal XRT or if >=50% radiation of pelvis; >=6 weeks must have elapsed if other substantial bone marrow irradiation was given.
Patients must have had their last fraction of:\r\n* Craniospinal irradiation >= 3 months prior to enrollment\r\n* Other substantial bone marrow irradiation >= 6 weeks prior to enrollment\r\n* Local palliative radiation therapy (XRT) (small port) >= 2 weeks
INCLUSION CRITERIA FOR STRATUM C: Patients must have had their last fraction of:\r\n* Craniospinal irradiation >= 3 months prior to enrollment\r\n* Other substantial bone marrow irradiation >= 6 weeks prior to enrollment\r\n* Local palliative radiation therapy (XRT) (small port) >= 2 weeks
At least 2 weeks must have elapsed since local radiation therapy (XRT) (small port); ? 3 months must have elapsed if prior cranial or craniospinal XRT was received, if ? 50% of the pelvis was irradiated, or if total body irradiation (TBI) was received; ? 6 weeks must have elapsed if other substantial bone marrow irradiation was given
Local palliative radiation therapy (XRT) (small port) ?2 weeks before first dose of study drug
Prior total body irradiation, total craniospinal XRT, or ?50% radiation of pelvis within 6 months of receiving first dose of study drug
Must not have received radiotherapy (XRT) within 14 days prior to study drug administration (small field) or 42 days for craniospinal XRT, or if ?50% radiation of pelvis.
Radiation therapy (XRT) >= 2 weeks for local palliative XRT; >= 6 months must have elapsed after XRT involving > 50% of the craniospinal axis or > 50% of the pelvis
Has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: At least 3 weeks since completion (6 weeks for nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least 7 days since completion of therapy with a biologic agent\r\n* Radiation (XRT): ? 1 week must have elapsed from prior palliative XRT to non-target lesions
Prior Therapy\r\n* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy\r\n** Cytotoxic chemotherapy (including investigational agents) or biologic agents (eg. cytokines or antibodies): At least 3 weeks after the last dose\r\n** Nitrosoureas/mitomycin C: At least 6 weeks from the last dose\r\n** Radiotherapy (XRT): At least 14 days after local palliative XRT (small port); at least 150 days must have elapsed if prior traumatic brain injury (TBI), craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow (BM) radiation; e.g. stem cell Infusion without TBI: no evidence of active graft versus (vs.) host disease and at least 56 days must have elapsed after transplant or stem cell infusion
Prior definitive radiation therapy (XRT) is allowed if it has been 2 weeks since the end of definitive XRT; for palliative XRT, protocol-specified treatment can begin at minimum 48 hours after completion of radiation; lesions within the XRT field can only be used as target lesions if definite progression has been demonstrated since the completion of radiation
At least 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); at least 6 weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); at least 3 months must have elapsed if prior craniospinal XRT was received, if more than 50% of the pelvis was irradiated, or if total body irradiation (TBI) was received; at least 6 weeks must have elapsed if other substantial bone marrow irradiation was given
The subject must have recovered from the acute toxic effects of all prior therapy with the exception of alopecia. The following time must have elapsed from the last dose of the following medications to study enrollment:\r\n* Myelosuppressive chemotherapy: 14 days\r\n* Hematopoietic growth factors: 7 days (14 days for Neulasta)\r\n* Biologic agent: 7 days\r\n* Monoclonal antibody: 3 half-lives \r\n* Immunotherapy (ie tumor vaccines): 42 days\r\n* Palliative small port radiation therapy (XRT): 14 days\r\n* Substantial bone marrow XRT: 6 weeks\r\n* Stem cell transplant or infusion without total body irradiation (TBI): 12 weeks\r\n* Total body irradiation (TBI): 24 weeks
Radiation therapy - At least 14 days must have elapsed for local XRT. At least 90 days must have elapsed if prior radiation to ?50% of the pelvis, the spine, or other substantial bone marrow radiation including TBI.
>= 2 weeks must have elapsed for local radiation therapy (XRT) (small port); >= 6 months must have elapsed if prior radiation to >= 50% of the pelvis or if other substantial bone marrow irradiation, including total body irradiation
Radiotherapy (XRT): at least 4 weeks for focal XRT or 8 weeks for craniospinal XRT must have elapsed prior to study entry
At least 14 days after local palliative XRT (small port); At least 150 days must have elapsed if prior TBI, craniospinal XRT or if ? 50% radiation of pelvis; At least 42 days must have elapsed if other substantial bone marrow radiation.
Patients must have had prior radiation therapy for treatment of their ependymoma; external beam radiation therapy (XRT) must be >= 3 months prior to registration for craniospinal irradiation (>= 18 Gray [Gy]); >= 4 weeks for local radiation to primary tumor; and >= 2 weeks prior to registration for focal irradiation to symptomatic metastatic sites
No radiation therapy >= 14 days for local palliative radiation therapy (XRT) (small port): >= 6 months must have elapsed if prior craniospinal XRT or if >= 50% radiation of pelvis; >= 42 days must have elapsed if other substantial bone marrow radiation
Radiation therapy (XRT)/External Beam Irradiation including Protons: ?14 days after local XRT, ?150 days after TBI, craniospinal XRT or if radiation to ?50% of the pelvis, ?42 days if other substantial BM radiation
Patients who require local palliative measures such as XRT or surgery
Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation; Note: patients must have received =< than 13.6 Gray (Gy) prior radiation to the mediastinum
External beam radiation therapy (XRT): at least 14 days after local palliative XRT (small port); at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if >= 50% radiation of pelvis; at least 42 days must have elapsed if other substantial bone marrow (BM) radiation
Patients with prior TBI, craniospinal XRT and/or those with >= 50% radiation of the pelvis are not eligible
Patients may have received palliative external beam radiation therapy (XRT) for local disease control with no curative intent; XRT must be completed at least 7 days prior to registration
>= 2 weeks (wks) for local palliative radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of MIBG; >= 6 months must have elapsed if prior total body irradiation (TBI), craniospinal XRT or >= 50% radiation of pelvis; >= 6 wks must have elapsed if other substantial bone marrow (BM) radiation
2 weeks for local palliative radiation therapy (XRT).
Radiotherapy (XRT)/External Beam Irradiation including Protons: ?14 days after local XRT; ?150 days after total body irradiation, craniospinal XRT or if radiation to ?50% of the pelvis; ?42 days if other substantial bone marrow radiation.
The following amounts of time must have elapsed prior to entry on study:\r\n* 2 weeks from local radiation therapy (XRT)\r\n* 8 weeks from prior craniospinal or if > 50% of the pelvis has been irradiated\r\n* 6 weeks must have elapsed if other bone marrow radiation has occurred
For all patients, >= 4 weeks must have elapsed for local external beam radiation therapy (XRT); >= 6 months must have elapsed if prior radiation to >= 50% of the pelvis or if substantial bone marrow irradiation; patients with a history of prior radiation with field including the heart (i.e. mantle) will be excluded
Craniospinal radiation therapy (XRT) is prohibited during protocol therapy; no washout period is necessary for radiation given to non-CNS chloromas; >= 90 days must have elapsed if prior traumatic brain injury (TBI) or craniospinal XRT
Patients must have had their last fraction of:\r\n* Craniospinal irradiation (> 24 Gray [Gy]) or total body irradiation > 3 months prior to registration\r\n* Local palliative external beam radiation therapy (XRT) (small port) >= 2 weeks \r\n* Other substantial bone marrow (BM) radiation >= 6 weeks must have elapsed
Radiotherapy: 3 weeks must have elapsed since radiation therapy (XRT)
>= 2 weeks must have elapsed for local palliative radiation therapy (XRT) (small port) and enrollment on study; at least 24 weeks must have elapsed since prior total body irradiation (TBI), radiation to >= 50% of pelvis, or craniospinal radiation; >= 6 weeks must have elapsed if the patient has received other substantial bone marrow (BM radiation); >= 6 weeks for prior metaiodobenzylguanidine (MIBG) therapy; for patients with only one site of measurable or evaluable disease, radiation must not have been given to that site unless that site has demonstrated clear progression after radiation or at least 2 months have elapsed since radiation and their remains evidence of viable tumor on biopsy, fludeoxyglucose (FDG) pet scan or MIBG scan
Has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: At least 3 weeks since completion (6 weeks for nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least 14 days since completion of therapy with a biologic agent\r\n* Radiation (XRT): >= 1 week must have elapsed from prior palliative XRT to non-target lesions
